Dynamic Functional Imaging Phenotyping and Disease Progression Risk Assessment in COPD Using Dynamic Chest Radiography: A Multicenter Retrospective Study
2 other identifiers
observational
2,500
1 country
1
Brief Summary
To evaluate the utility of DCR-derived parameters for identifying dynamic functional imaging phenotypes, assessing disease severity, and predicting the risk of disease progression in COPD.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Aug 2026
Typical duration for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
August 3, 2026
CompletedFirst Submitted
Initial submission to the registry
August 9, 2026
CompletedFirst Posted
Study publicly available on registry
August 13, 2026
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 30, 2029
ExpectedStudy Completion
Last participant's last visit for all outcomes
January 30, 2030
August 13, 2026
August 1, 2026
3.4 years
August 9, 2026
August 9, 2026
Conditions
Keywords
Outcome Measures
Primary Outcomes (11)
Exacerbation/respiratory history and event
Measurement of disease control and burden
At Baseline
FEV1 %
Measurement of lung function
At Baseline
FEV1 /FVC
Measurement of lung function
At Baseline
Emphysema
Measurement of chest CT
At Baseline
diaphragm movement
Measurement of Dynamic chest radiograph
At Baseline
lung field area
Measurement of Dynamic chest radiograph
At Baseline
lung field area change rate
Measurement of Dynamic chest radiograph
At Baseline
CAT
Measurement of questionnaires
At Baseline
SGRQ
Measurement of questionnaires
At Baseline
mMRC
Measurement of questionnaires
At Baseline
Smoking history and status
Risk factors of COPD development or lung function decline
At Baseline
Study Arms (4)
COPD group
any patient who complains of dyspnea, chronic cough or sputum, a history of recurrent lower respiratory infection and/or a history of exposure to disease risk factors, Pulmonary function examination indicated that FEV1/FVC \<0.7 after bronchodilator was used to confirm COPD.
PRISM group
After bronchial dilation, FEV1/FVC was ≥0.70, and FEV1%PRED was \<80%.
Smoking exposure groups
Smoking history of 10 years, or without COPD, pulmonary function of COPD diagnosis standard.
Normal control group
Never-smokers without airflow limitation and with normal pulmonary function.
Eligibility Criteria
Chronic obstructive pulmonary disease (COPD) is a heterogeneous lung condition characterized by chronic respiratory symptoms, including dyspnea, cough, and sputum production. These symptoms result from airway abnormalities, such as bronchitis or bronchiolitis, and/or alveolar abnormalities, such as emphysema, that cause persistent and often progressive airflow obstruction.
You may qualify if:
- Aged 30-85 years.
- Male or female.
- Patients who underwent pulmonary function testing and dynamic chest radiography at the hospital.
You may not qualify if:
- Incomplete medical records.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Nanfang Hospital, Southern Medical University
Guangzhou, Guangdong, 510400, China
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- STUDY CHAIR
Laiyu Liu, professor
Nanfang Hospital, Southern Medical University
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- RETROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
August 9, 2026
First Posted
August 13, 2026
Study Start
August 3, 2026
Primary Completion (Estimated)
December 30, 2029
Study Completion (Estimated)
January 30, 2030
Last Updated
August 13, 2026
Record last verified: 2026-08